RetaCalc
Protocol library
SinglePreclinicalPreclinicalVery Low confidenceSourced

Cartalax

A short peptide bioregulator marketed for cartilage-related claims. Internationally indexed controlled human evidence is too sparse to establish a protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational bioregulator schedule

2 mg daily in weeks 1-2, 3 mg in weeks 3-4, 4 mg in weeks 5-8 and 5 mg in weeks 9-12

The guide itself notes the absence of a matched human randomised dose-finding programme. These are retail educational conventions, not validated posology.

View source

Evidence summary

A short peptide bioregulator marketed for cartilage-related claims. Internationally indexed controlled human evidence is too sparse to establish a protocol.

Protocol basis

The page records the evidence search and absence of a reproducible indexed human schedule rather than filling the gap with vendor conventions.

What remains uncertain

Human pharmacokinetics, controlled efficacy, adverse-event frequency and a validated formulation remain unknown.

Warnings and contraindications

No adequate controlled human regimen was identified in major indexed literature.
Brand or bioregulator claims are not substitutes for clinical outcomes.
Identity, formulation and route-specific safety require independent verification.